Data gathered: November 8
Alternative Data for Eagle Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,575 | Sign up | Sign up | Sign up |
| Twitter Mentions | 18 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and marketing injectable products primarily in the areas of metabolic critical care and oncology in the United States. The company is headquartered in Woodcliff Lake, New Jersey.
| Price | $0.85 |
| Target Price | Sign up |
| Volume | 33,840 |
| Market Cap | $9.1M |
| Year Range | $0.35 - $6.51 |
| Dividend Yield | 0% |
| PE Ratio | 0.82 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanOctober 30 - Yahoo |
Eagle Pharmaceuticals Implements Stockholder Rights PlanOctober 30 - TipRanks |
|
Union Square Park Capital Management, LLC Increases Stake in Eagle Pharmaceuticals IncOctober 30 - GuruFocus |
|
 |
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)October 29 - ETF Daily News |
|
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.comOctober 21 - ETF Daily News |
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More InformationOctober 14 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '23 | 63M | 50M | 13M | 5.2M | 16M | 1.180 |
| Q1 '23 | 65M | 51M | 14M | 5.8M | 17M | 1.260 |
| Q4 '22 | 66M | 50M | 17M | 8.2M | 21M | 1.100 |
| Q3 '22 | 65M | 51M | 14M | -7.1M | 1.2M | 1.120 |
| Q2 '22 | 74M | 62M | 12M | -9.5M | -3.8M | 1.560 |
Insider Transactions View All
| Tarriff Scott filed to sell 545,447 shares at $13.9. November 3 '23 |
| Tarriff Scott filed to sell 556,141 shares at $13.8. November 3 '23 |
| Tarriff Scott filed to sell 567,066 shares at $15.1. October 4 '23 |
| Tarriff Scott filed to sell 567,776 shares at $14.4. October 4 '23 |
| Tarriff Scott filed to sell 577,800 shares at $15.2. October 4 '23 |
Similar companies
Read more about Eagle Pharmaceuticals (EGRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Eagle Pharmaceuticals?
The Market Cap of Eagle Pharmaceuticals is $9.1M.
What is Eagle Pharmaceuticals' PE Ratio?
As of today, Eagle Pharmaceuticals' PE (Price to Earnings) ratio is 0.82.
What is the current stock price of Eagle Pharmaceuticals?
Currently, the price of one share of Eagle Pharmaceuticals stock is $0.85.
How can I analyze the EGRX stock price chart for investment decisions?
The EGRX stock price chart above provides a comprehensive visual representation of Eagle Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eagle Pharmaceuticals shares. Our platform offers an up-to-date EGRX stock price chart, along with technical data analysis and alternative data insights.
Does EGRX offer dividends to its shareholders?
As of our latest update, Eagle Pharmaceuticals (EGRX) does not offer dividends to its shareholders. Investors interested in Eagle Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Eagle Pharmaceuticals?
Some of the similar stocks of Eagle Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.